Page 166 - Neuropsychiatric.indd

2. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: 17. Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, et al. Fluoroquinolones
mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241-53. and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug

3. สัญญา ร้อยสมมติ. หัวใจและการไหลเวียนเลือด เล่ม 1. ขอนแก่น; 2555. Saf. 2019;42(4):529-538.
ิ
ุ
ิ
4. เจรญลาภ อุทานปทมรส. Basic ECG Interpretation. [เข้าถึง 20 พฤศจกายน 2563]. จาก: 18. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence,
http://www.thaiheart.org/images/sub_1296823951/ECG%20interpretation.pdf diagnosis, and management of qt prolongation induced by cancer therapies: a systematic
5. Okutucu S, Oto A. Fundamentals of ECG. In: Interpreting ECGs in Clinical Practice. review. J Am Heart Assoc. 2017;6(12):e007724.
Switzerland: Springer, 2018. 19. Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse
6. Becker DE. Fundamentals of electrocardiography interpretation. Anesth Prog. 2006 events in the mortality difference between first and second-generation antipsychotics in
Summer; 53(2):53-63. older adults: systematic review and meta-synthesis. PLoS One. 2014;9(8):e105376.

7. Antzelevitch C, Burashnikov A. Overview of basic mechanisms of cardiac arrhythmia. Card 20. Arellano-Rodrigo E, Garcia A, Mont L, Roque M. Torsade de pointes and cardiorespiratory
Electrophysiol Clin. 2011;3(1):23-45. arrest induced by azithromycin in a patient with congenital long QT syndrome. Medicina
8. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 Clinica. 2001;117: 118-9.
AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the 21. Huang B, Wu C, Hsia C, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin
prevention of sudden cardiac death: Executive summary: A Report of the American College Electrophysiol. 2007;30: 1579-82.

of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and 22. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher J. Azithromycin as a cause of QT-interval
the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e190-e252. prolongation and torsade de pointes in the absence of other known precipitating factors.
9. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al. Drug- J Intervent Cardiac Electrophysiol. 2007;18:243-6.

Induced arrhythmias: A scientific statement from the American Heart Association. 23. Winton J, Twilla J. Sudden cardiac arrest in a patient on chronic methadone after the
Circulation. 2020;142(15):e214-e33. addition of azithromycin. Am J Med Sci. 2013;345:160-2.
10. Tisdale JE. Chapter 25 Ventricular arrhythmia. In: Tisdale JE et al., eds. Drug-Induced 24. Hancox JC. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de
Diseases: Prevention, Detection, and Management. 3rd ed. United States: American Society pointes, and regulatory issues: A narrative review based on the study of case reports. Ther

of Health-System Pharmacists, Inc., 2018. Adv Infect Dis. 2013;1(5): 155–65.
11. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval 25. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade
prolongation. Br J Clin Pharmacol. 2010;70(1):16-23. de pointes in hospital settings: a scientific statement from the American Heart Association
12. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013- and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047-60.

22. 26. Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-
®
13. CredibleMeds . QT Drugs Lists. [accessed 29 November 2020]. Available from prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16-25.
https://www.crediblemeds.org. 27. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the
14. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. Meta- pharmacist in risk assessment, prevention and management. Can Pharm J (Ott).

analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin 2016;149(3):139-52.
Psychiatry. 2014;75(5):e441-9. 28. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al.
15. Diaz-Arocutipa C, Brañez-Condorena A, Hernandez AV. QTc prolongation in COVID-19 Development and validation of a risk score to predict QT interval prolongation in
patients treated with hydroxychloroquine, chloroquine, azithromycin, or hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-87.

lopinavir/ritonavir: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 29. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ.
2021;30(6):694-706. Effectiveness of a clinical decision support system for reducing the risk of QT interval
16. Bor S, Demir M, Ozdemir O, Yuksel K. A meta-analysis on the cardiac safety profile of prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381-90.
domperidone compared to metoclopramide. United European Gastroenterol J.

2018;6(9):1331-46.

144 145
145